NasdaqGS - Nasdaq Real Time Price • USD
Gilead Sciences, Inc. (GILD)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:56 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 23 | 19 | 29 |
| Avg. Estimate | -1.39 | 1.58 | 3.67 | 6.82 |
| Low Estimate | -1.73 | 1.32 | 3.23 | 6.18 |
| High Estimate | -1.06 | 1.92 | 4.33 | 7.71 |
| Year Ago EPS | 1.37 | 1.34 | 6.28 | 3.67 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 22 | 20 | 29 | 29 |
| Avg. Estimate | 5.92B | 6.33B | 25.69B | 26.14B |
| Low Estimate | 5.58B | 6.13B | 25.32B | 25.45B |
| High Estimate | 6.33B | 6.54B | 26.19B | 27.02B |
| Year Ago Sales | 6.35B | 6.6B | 25.33B | 25.69B |
| Sales Growth (year/est) | -6.80% | -4.10% | 1.40% | 1.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.54 | 1.64 | 1.92 | 1.64 |
| EPS Actual | 1.37 | 1.34 | 2.29 | 1.61 |
| Difference | -0.17 | -0.3 | 0.37 | -0.03 |
| Surprise % | -11.00% | -18.30% | 19.30% | -1.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.39 | 1.58 | 3.67 | 6.82 |
| 7 Days Ago | 0.37 | 1.59 | 5.79 | 6.9 |
| 30 Days Ago | 1.58 | 1.71 | 7.09 | 7.43 |
| 60 Days Ago | 1.58 | 1.71 | 7.1 | 7.44 |
| 90 Days Ago | 1.73 | 1.79 | 7.22 | 7.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 3 |
| Up Last 30 Days | -- | 2 | 1 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 4 | 1 | 7 | 2 |
Growth Estimates
| CURRENCY IN USD | GILD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -201.50% | -- | -- | 2.60% |
| Next Qtr. | 17.90% | -- | -- | 13.40% |
| Current Year | -41.60% | -- | -- | 5.20% |
| Next Year | 85.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 5.02% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 1.66% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | HSBC: Reduce to Hold | 4/24/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/19/2024 |
| Maintains | UBS: Neutral to Neutral | 4/17/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 3/4/2024 |
| Maintains | Mizuho: Buy to Buy | 2/22/2024 |
| Downgrade | Truist Securities: Buy to Hold | 2/22/2024 |
Related Tickers
BMY Bristol-Myers Squibb Company
44.70
-8.51%
BIIB Biogen Inc.
202.46
+0.23%
AMGN Amgen Inc.
269.38
-1.33%
PFE Pfizer Inc.
25.26
-3.84%
ABBV AbbVie Inc.
167.29
-0.30%
MRK Merck & Co., Inc.
130.72
+2.93%
JNJ Johnson & Johnson
146.82
-1.15%
GSK GSK plc
40.91
+0.12%
AZN AstraZeneca PLC
75.03
+5.38%
NVS Novartis AG
99.06
+0.72%